AMC

The 2013 Pneumococcal AMC Annual Report gives an overview of the activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2012 to 31 March 2013. During this period a third tender was issued in response to the high level of country demand and eight countries introduced pneumococcal vaccines procured through the AMC, taking the total to 24 introductions by March 2013.

Pneumococcal AMC: OECD GDP Deflator Data Purpose: As per the Pneumococcal AMC Inflation Review Application Process, listed below is the OECD GDP Deflator to be used to calculate an inflation adjustment request. BASE QTR Q2-2009 Q2-2010 Q2-2011 Q2-2012 Q2-2013 Q2-2014 Q2-2015 Q2-2016 Q2-2017 Q2-2018 Q2-2019 Q2-2020 Q2-2

ACCELERATE VACCINE INTRODUCTION – PNEUMOCOCCAL CONJUGATE VACCINE Strategic Demand Forecast (Required Supply) Version 5.0 – updated in March 2012 Published – 13 August 2012 This version 5.0 is issued in accordance with the AVI Forecasting Standard Operating Procedure.

Remaining AMC offer amount: June 2012

The 2012 Pneumococcal AMC Annual Report gives an overview of all activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2011 to 31 March 2012. It provides an extensive description of the first achievements of this innovative initiative: the first introductions of pneumococcal vaccines in GAVI countries.

Frequently asked questions about Advance Market Commitments for vaccines for manufacturers.

The official formal notification of the remaining AMC Offer Amount.

The 2011 Pneumococcal AMC Annual Report gives an overview of all activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2010 to 31 March 2011.

This version 3.0 is issued in accordance with the AVI Forecasting Standard Operating Procedure. The forecast captures all AMC‐eligible demand including countries that: introduce with GAVI support, graduate from GAVI support, and are fully self-financed.

List of modifications to the AMC legal agreements.

Offer agreement relating to the Advance Market Commitment for pneumococcal vaccines.

This Procedures Memorandum describes the procedures that would be applicable to any AMC.

AMC deed of amendment and restatement relating to the Advance Market Commitment for pneumococcal vaccines offer agreement, IAC Charter & bylaws and procedures memorandum orginally dated 12 June 2009.

The AMC Baseline Study presents an innovative new approach to public health funding as a way of stimulating and accelerating the development and manufacture of vaccines for developing countries.

The serotype replacement issue arises from extensive use of pneumococcal conjugate vaccine, which is expected to result in some increase of disease occurence due to serotypes not in the vaccine. This raises question whether the increases could reach a point where the benefit of the vaccine is lost, or the increases will be small relative to the decline in vaccine type disease.

The purpose of the meeting was to review Pfizer’s application for AMC eligibility for Prevenar 13 and determine if the candidate vaccine met the TPP for the AMC.

The process for manufacturers interested in submitting an Inflation Review Application.

The official formal notification of the remaining AMC Offer Amount.

PneumoADIP is a small, dedicated team based at Johns Hopkins Bloomberg School of Public Health, supported by a $30 million grant from the GAVI Alliance.

Minutes from AMC Eligibility Determination Meeting held in London, UK on 16 April 2010.

This progress report presents an overview of the activities linked to the implementation of the pneumococcal AMC since the signature of the legal agreements on 12 June 2009 up until 31 March 2010. It was developed by the AMC Secretariat at GAVI, in collaboration with the World Bank and UNICEF’s Supply Division, and was approved by the Independent Assessment Committee on 13 April 2010.

List of IAC members.

The selection process for Independent Assessment Committee (IAC) members is administered by the GAVI Alliance Secretariat, in its role as AMC Secretariat. Evaluation of candidates is conducted by a selection panel composed of five international leaders on global health issues.

A case study on the multi-sector effort to build a financing mechanism, the AMC, as an incentive to facilitate vaccine development.

The process of the Pneumococcal AMC involves donors, IBRD, UNICEF, suppliers, the AMC Independent Assessment Committee (IAC), developing countries and participating manufacturers.